Market eyes KIP's Global Pharma PEF The fund with 135 billion won committed capital is likely to generate high returns
Translated by Kim So-in 공개 2019-10-15 08:00:00
이 기사는 2019년 10월 15일 08:00 thebell 에 표출된 기사입니다.
South Korea's Pharmaceutical and Bio-Pharma private equity fund (PEF), managed by Korea Investment Partners (KIP) is gaining attention. The big fund is anticipated to generate high returns amid a boom in pharmaceutical and bio-pharma industry.According to industry sources on October 7, 'Korea Investment Global Pharmaceutical Industry Promotion Private Equity Fund (Global Pharma PEF)' invested 12 billion won in TiumBio and owns over 3.62 million shares. TiumBio kicked off its initial public offering (IPO) on KOSDAQ. Based on the bottom end of the IPO pricing range, Global Pharma PEF's shares are worth around 58 billion won.
Global Pharma PEF was created in 2015 with 135 billion won in committed capital. It was part of the Ministry of Health and Welfare (MOHW)'s project to promote and nurture pharmaceutical and bio-pharma companies whose technology is promising but capital strength is weak. MOWH (20 billion won), Korea Finance Corporation (50 billion won), Korea Investment & Securities (10 billon won), KIP (20 billion) invested in the PEF.
Targeting domestic and overseas pharmaceutical and bio-pharma companies, the fund has deployed over 120 billion won. Funds managed by venture capital firms normally spend 85~90 percent of total commitments, considering management fee and operating cost.
The fund invested 5 billion won in Ahngook Pharm and AGBIO Diagnostics, respectively and 10 billion won in Handok Kalos Medical. It also invested in three affiliates of Huons Group - Huons Medicare, Huons Natural, and Biotopia.
Global Pharma PEF's investment ranges from mezzanines issued by listed companies to equity investment in private companies. Most of the listed companies, such as HLB, Lego Chem Bio, and CTC Bio have a long history with the PEF.
Among private companies, the fund invested in ABL Bio (11 billion won), Denflex (2 billion won), Precision Biosensor (2.4 billion won), TiumBio (9 billion won), Gencurix (2 billion won), BioSynetics (3 billion won), and Genome & Company (4 billion won). The fund also invested in the overseas bio-pharma companies, such as Elastagen in Australia (5 million dollar) and Eloxx Pharmaceutical in Israel (4.4 billion won).
ABL Bio, which the fund strategically invested in, like it did with TiumBio, made its stock market debut last year. The fund owns over 3.8 million shares in the company, which equates to 68 billion won based on the current stock price of 18 thousand won. In April, the fund sold its shares in ABL Bio for approximately 60 billion won. TiumBio and ABL Bio alone already surpass committed capital.
The fund also exited its investment in Elastagen with Allergan's acquisition of Elastagen, returning multiple of four times. The fund also exited from HLB.
"It is hard for funds with large capital commitments to record high returns compared with fund with small commitments. As far as I know, Global Pharma PEF has a unique strategy for high returns, which begins with incubating promising bio-pharma companies," said one venture capital industry source.
(By reporter Lee Youn-jae)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [노바렉스를 움직이는 사람들]권수혜 전략기획총괄, 노바렉스 미래 그리는 지휘자
- [K-배터리 밸류업 리포트]제이오, 도전재 넘어 다각화 시동
- [이스트소프트는 지금]'알약 IPO' 특명받은 정진일 대표, 문제는 '기업가치'
- 지닥, 위믹스 많은데 '박관호 위메이드 대표 몫 못 줘'
- [탈엔비디아를 꿈꾸는 기업들]'AI 반도체 양산 임박' 모빌린트, 시험대 오른다
- [Company Watch]'애플과 멀어진' LX세미콘, DDI 대안 시급
- 외화 조달 나선 카카오, 글로벌 AI 진출 신호탄 쐈다
- [VC 투자기업]'애드테크' 버즈빌, 영업권 손상차손 93억 발생 '왜'
- [VC 투자기업]모비두, 이커머스와 매출 '윈윈' 핵심은 소스애드
- [VC 투자기업]‘전자문서 서비스’ 자버, 30억 시리즈A 나선다